0QNV Stock Chart & Stats
$0.02
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$0.02 - $0.07
Previous CloseN/A
VolumeN/A
Average Volume (3M)84.97K
Market Cap
CHF2.90M
Enterprise Value$4.26
Total Cash (Recent Filing)CHF937.50K
Total Debt (Recent Filing)CHF102.27K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding218,654,500
10 Day Avg. Volume103,200
30 Day Avg. Volume84,966
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)35.91
P/FCF Ratio-2.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal Leverage Supports Financial FlexibilityVery low leverage limits fixed financial obligations and reduces balance-sheet risk relative to more highly indebted biotech companies. This gives Addex greater flexibility to direct available capital toward development programs and partnerships, although it does not eliminate the need for external funding.
Broadened Proprietary Pipeline And RightsRegaining full rights expands Addex’s control over development strategy, indications, partnering, and potential monetization of the GABAB PAM portfolio. Combined with multiple candidates and differentiated leads, this creates more strategic optionality than a single-asset pipeline would provide.
Extended Runway Enables Near-term MilestonesThe financing and stated runway provide time to pursue several value-defining development events, including NTX-253 Phase I data and IND progress for other programs. More funding visibility can support disciplined execution and improve the company’s ability to negotiate partnerships from a stronger position.
Bears Say
Severe Revenue Contraction And Persistent LossesAddex remains dependent on development-stage monetization rather than product sales, while revenue has contracted materially and large losses continue. This weak operating base limits internal reinvestment capacity and makes future progress heavily dependent on successful partnering, milestones, or additional financing.
Persistent Cash Burn And Funding DependenceNegative operating and free cash flow show that current activities do not fund themselves, even though the rate of burn has moderated from earlier years. Continued clinical advancement therefore depends on external capital or partners, creating execution risk if financing is delayed or expensive.
Variable Revenue Model Lacks Approved-product SupportThe business model relies on collaborations, milestones, licensing fees, and future royalties rather than established product sales. Those sources are inherently dependent on clinical, regulatory, and partnering outcomes, so revenue visibility and operating leverage may remain uneven over the next several quarters.
Addex Therapeutics News
0QNV FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest share price was $0.02 and its highest was $0.07 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is CHF2.90M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 42 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Sep 28, 2026. The company reported -$0.01 earnings per share for the quarter.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Undervalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 218,654,500 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -$0.01 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in GB:0QNV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.